On Tuesday, Morgan Stanley sustained its Equalweight rating for Bayer AG (ETR:BAYGN) (BAYN:GR) (OTC: BAYRY), with a consistent price target of EUR45.00. The firm's analysis of Bayer (OTC:BAYRY)'s first-quarter financial results for 2024 highlighted a mixed performance with certain segments outpacing expectations while others fell short.
Bayer's earnings before interest, taxes, depreciation, and amortization (EBITDA) surpassed forecasts, despite group sales not meeting expectations with a 2% shortfall. The EBITDA outperformance, which was 6% higher than anticipated and an 18% beat on earnings per share (EPS), was attributed to reconciliation items. Adjusting for these, the underlying EBITDA beat was 3% across the company's divisions.
The pharmaceutical division of Bayer experienced a 1% sales beat and a 3% EBITDA beat. This was largely due to robust sales of Xarelto and Adempas in the United States, which compensated for weaker performance from Adalat in China, affected by the Volume-Based Procurement (VBP) program, and a dip in demand for Aspirin in the same market.
In contrast, the Crop Science division reported a 2% miss on sales but managed a 5% EBITDA beat. This was despite decreased volumes in non-glyphosate-based herbicides and the fungicides business within Europe, the Middle East, and Africa (EMEA).
Consumer Health was the weakest link in Bayer's portfolio, missing sales targets by 9% and EBITDA predictions by 10%. The division faced challenges including lower customer demand following a restocking period in the fourth quarter of 2023 and inventory adjustments by U.S. retailers in the first quarter of 2024. Additionally, a milder winter season impacted the demand for cough and cold products. However, some of these negative effects were mitigated by positive pricing strategies.
InvestingPro Insights
As Morgan Stanley maintains its stance on Bayer AG, real-time data and InvestingPro Tips can provide additional context for investors considering the stock. Bayer's market capitalization currently stands at $32.16 billion, reflecting its significant presence in the market. Despite recent performance concerns, the company's P/E ratio has improved to 8.15 in the last twelve months as of Q1 2024, suggesting a potential undervaluation compared to historical averages. Additionally, the PEG ratio, which indicates the stock's value while taking into account expected earnings growth, is remarkably low at 0.06, hinting at a stock that may be undervalued relative to its growth prospects.
InvestingPro Tips highlight that Bayer is anticipated to see net income growth this year, which aligns with the positive EBITDA performance noted by Morgan Stanley. The stock's current overbought status according to the RSI could be a point of caution for short-term investors, but the company's strong free cash flow yield and low price volatility might appeal to those with a longer investment horizon. With 33 years of consistent dividend payments, Bayer remains a stalwart in the Pharmaceuticals industry. For investors seeking a deeper analysis, there are additional InvestingPro Tips available, which can be accessed through InvestingPro's platform, including insights on profitability forecasts for the year ahead.
Interested readers can take advantage of an exclusive offer using the coupon code PRONEWS24 to receive an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which includes an array of comprehensive investing tools and insights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.